Unknown

Dataset Information

0

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Illidge TM 

PROVIDER: S-EPMC6960465 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.

Illidge Tim M TM   Phillips Elizabeth H EH   Counsell Nicholas N   Pettengell Ruth R   Johnson Peter W M PWM   Culligan Dominic J DJ   Popova Bilyana B   Clifton-Hadley Laura L   McMillan Andrew A   Hoskin Peter P   Barrington Sally F SF   Radford John J  

Blood advances 20200101 1

Similar Datasets

Unknown Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.
| S-EPMC12124608 | biostudies-literature
Unknown Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.
| S-EPMC8945315 | biostudies-literature
Unknown PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
| S-EPMC6633886 | biostudies-literature
Unknown Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD.
| S-EPMC6269305 | biostudies-literature
Unknown Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone.
| S-EPMC11488433 | biostudies-literature
Unknown Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
| S-EPMC3790950 | biostudies-literature
Unknown PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
| S-EPMC8553182 | biostudies-literature
Unknown Prognostic Value of Massiveness Parameters Measured on Baseline FDG PET in Advanced-Stage Hodgkin Lymphoma.
| S-EPMC12701620 | biostudies-literature
Unknown CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
| S-EPMC6128083 | biostudies-literature
Unknown The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
| S-EPMC4467863 | biostudies-literature